Andres Meraz-Brenez, Medical Oncologist at Mexican Social Security Institute, shared a post on X:
“New paper out in JCO Global Oncology.
CDK4/6 inhibitors have transformed HR+/HER2- breast cancer… but in Latin America, access still defines treatment.
Survey of 116 oncologists across 15 countries (in collaboration with LABCA | Latin American Breast Cancer Association):
- Ribociclib most preferred (driven by overall survival benefit across trials)
- Abemaciclib – endocrine resistance/CNS
- Palbociclib – elderly/male patients Biggest gap: institutional access, not evidence.”
Title: Preferences in Cyclin-Dependent Kinase 4/6 Inhibitors for Advanced Breast Cancer Among Medical Oncologists in Latin America
Authors: Cynthia Villarreal-Garza, Andres Meraz-Brenez, Agatha Reyes Morales, Ahmad Wali Mushtaq, Brizio Moreno-Jaime, Denis U. Landaverde, Fernando E. Petracci, Henry Idrobo Quintero, Joel Moreno Ríos, Juan Carlos Samamé Pérez-Vargas, Victor Acosta Marín, William Armando Man
Read the Full Article.
HER2-Positive Breast Cancer Treatment: A Comprehensive Guide for Clinicians in 2026
